Following the success of its Covid-19 vaccine, Moderna (NASDAQ:MRNA) is hoping to add more arsenal to its product line; going by the latest update from its pipeline, that could soon
Following the success of its Covid-19 vaccine, Moderna (NASDAQ:MRNA) is hoping to add more arsenal to its product line; going by the latest update from its pipeline, that could soon
After sort of winning the World Cup with its first commercial offering, the Covid-19 vaccine Spikevax, questions have been raised on whether Moderna (MRNA) can follow up its success. That
While Moderna (MRNA) has seen enormous success for its Covid-19 vaccine mRNA-1273 (Spikevax), to-date it is still its only approved product. And with the pandemic waning in most parts of
Recently, Moderna (MRNA) held its third annual vaccine day, where the company provided an update on its pipeline. While Moderna is primarily known for the outstanding success of its Covid-19